KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clearfield (CLFD) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Clearfield (CLFD) over the last 16 years, with Sep 2025 value amounting to $21.5 million.

  • Clearfield's Cash & Equivalents rose 51.92% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 51.92%. This contributed to the annual value of $21.5 million for FY2025, which is 51.92% up from last year.
  • According to the latest figures from Q3 2025, Clearfield's Cash & Equivalents is $21.5 million, which was down 36.54% from $33.9 million recorded in Q2 2025.
  • Over the past 5 years, Clearfield's Cash & Equivalents peaked at $37.8 million during Q3 2023, and registered a low of $12.7 million during Q4 2021.
  • In the last 3 years, Clearfield's Cash & Equivalents had a median value of $29.7 million in 2024 and averaged $27.4 million.
  • As far as peak fluctuations go, Clearfield's Cash & Equivalents skyrocketed by 160.49% in 2021, and later plummeted by 62.60% in 2024.
  • Clearfield's Cash & Equivalents (MRQ) stood at $12.7 million in 2021, then surged by 139.02% to $30.3 million in 2022, then rose by 13.76% to $34.5 million in 2023, then fell by 11.69% to $30.5 million in 2024, then dropped by 29.42% to $21.5 million in 2025.
  • Its Cash & Equivalents stands at $21.5 million for Q3 2025, versus $33.9 million for Q2 2025 and $28.8 million for Q1 2025.